| Stock | Role | Class | Num Shares | Value | Price $ | Report Date | Ownership |
|---|---|---|---|---|---|---|---|
| INCYTE CORP | Director, 10%+ Owner | Common Stock | 28.2M | $2.36B | $83.70 | Sep 30, 2025 | Indirect |
| BeiGene, Ltd. | Director | American Depositary Shares | 8.07M | $2.1B | $260.00 | May 21, 2025 | Indirect |
| MADRIGAL PHARMACEUTICALS, INC. | Director | Common Stock | 1.95M | $764M | $392.24 | Aug 20, 2025 | Indirect |
| ACADIA PHARMACEUTICALS INC | Director, 10%+ Owner | Common Stock | 39.4M | $687M | $17.44 | May 29, 2025 | Indirect |
| Kymera Therapeutics, Inc. | Director | Prefunded Warrants | 10.2M | $450M | $44.00 | Jun 30, 2025 | Indirect |
| BICYCLE THERAPEUTICS PLC | Director, 10%+ Owner | Non-Voting Ordinary Shares | 17.8M | $382M | $21.42 | Jun 17, 2024 | Indirect |
| Kymera Therapeutics, Inc. | Director | Common Stock | 6.12M | $269M | $44.00 | Jun 30, 2025 | Indirect |
| BICYCLE THERAPEUTICS PLC | Director, 10%+ Owner | American Depositary Shares | 10M | $153M | $15.34 | Jan 2, 2025 | Indirect |
| Replimune Group, Inc. | Director, 10%+ Owner | Common Stock | 10.1M | $126M | $12.42 | Mar 5, 2025 | Indirect |
| Celcuity Inc. | 10%+ Owner | Common Stock | 7.06M | $77.9M | $11.04 | Aug 1, 2025 | Indirect |
| Kiniksa Pharmaceuticals International, plc | Director | Class A Ordinary Shares | 2.74M | $70.1M | $25.60 | Jun 3, 2025 | Indirect |
| Immunocore Holdings plc | Director | American Depositary Shares | 2.14M | $63.4M | $29.56 | Mar 17, 2025 | Indirect |
| Denali Therapeutics Inc. | Director | Common Stock | 3.42M | $56.2M | $16.44 | Jun 3, 2025 | Indirect |
| Entrada Therapeutics, Inc. | 10%+ Owner | Warrants to purchase Common Stock | 3.08M | $45.8M | $14.85 | Jun 25, 2024 | Indirect |
| BeiGene, Ltd. | Director | Ordinary Shares | 148K | $36.3M | $244.90 | May 21, 2025 | Indirect |
| INCYTE CORP | Director, 10%+ Owner | Common Stock | 281K | $23.5M | $83.70 | Sep 30, 2025 | Direct |
| BeiGene, Ltd. | Director | American Depositary Shares | 10.4K | $2.71M | $260.00 | May 21, 2025 | Direct |
| ACADIA PHARMACEUTICALS INC | Director, 10%+ Owner | Common Stock | 103K | $1.79M | $17.44 | May 29, 2025 | Direct |
| Atreca, Inc. | Former 10% Owner | Class A common stock | 2.97M | $1.2M | $0.40 | Oct 19, 2023 | Indirect |
| KALA BIO, Inc. | Former 10% owner | Common Stock | 425K | $588K | $1.38 | Oct 1, 2025 | Indirect |
| Kiniksa Pharmaceuticals International, plc | Director | Class A Ordinary Shares | 14.8K | $380K | $25.60 | Jun 3, 2025 | Direct |
| Neurogene Inc. | Director, Former 10% Owner | Common Stock | 415K | $287K | $0.69 | Dec 18, 2023 | Indirect |
| BeiGene, Ltd. | Director | Ordinary Shares | 1 | $244 | $244.90 | May 21, 2025 | Direct |
| Neurogene Inc. | Director, Former 10% Owner | Common Stock | 113 | $78.00 | $0.69 | Dec 18, 2023 | Direct |
| IGM Biosciences, Inc. | Former 10% owner and director | Common Stock | 0 | $0 | $1.27 | Aug 14, 2025 | Indirect |
| DBV Technologies S.A. | Director, 10%+ Owner | BS Warrant | 25M | Mar 27, 2025 | Indirect | ||
| DBV Technologies S.A. | Director, 10%+ Owner | First Pre-Funded Warrant | 25M | Mar 27, 2025 | Indirect | ||
| BELLICUM PHARMACEUTICALS, INC | 10%+ Owner | Warrants (right to buy) | 14.2M | Nov 22, 2023 | Indirect | ||
| vTv Therapeutics Inc. | Director | Prefunded Warrants | 5.18M | Sep 3, 2025 | Indirect | ||
| SERA PROGNOSTICS, INC. | 10%+ Owner | Common Stock | 5.07M | Feb 12, 2025 | Indirect | ||
| Kiniksa Pharmaceuticals, Ltd. | Director | Class A Common Shares | 2.73M | Jun 5, 2024 | Indirect | ||
| Neurogene Inc. | Director, Former 10% Owner | Prefunded Warrants | 2.66M | Dec 18, 2023 | Indirect | ||
| vTv Therapeutics Inc. | Director | Common Warrant | 2.4M | Sep 3, 2025 | Indirect | ||
| BELLICUM PHARMACEUTICALS, INC | 10%+ Owner | Common Stock | 2.17M | Nov 22, 2023 | Indirect | ||
| Neoleukin Therapeutics, Inc. | Director, Former 10% Owner | Pre-funded Warrants | 1.52M | Oct 5, 2023 | Indirect | ||
| vTv Therapeutics Inc. | Director | Common Stock | 136K | Sep 3, 2025 | Indirect | ||
| Prelude Therapeutics Inc | Director, 10%+ Owner | Non- Qualified Stock Option (right to buy) | 76K | Jun 12, 2025 | Indirect | ||
| TScan Therapeutics, Inc. | Director | Non- Qualified Stock Option (right to buy) | 67K | Jun 30, 2025 | Indirect | ||
| Replimune Group, Inc. | Director, 10%+ Owner | Non-Qualified Stock Option (right to buy)uy) | 64K | Mar 5, 2025 | Indirect | ||
| Kiniksa Pharmaceuticals International, plc | Director | Non- Qualified Share Option (right to buy) | 50.4K | Jun 3, 2025 | Indirect | ||
| BeiGene, Ltd. | Director | Share Option (Right to Buy) | 45.5K | May 21, 2025 | Indirect | ||
| Aeglea BioTherapeutics, Inc. | Director | Non-Qualified Stock Option (right to buy) | 40K | Jun 8, 2021 | Indirect | ||
| Kodiak Sciences Inc. | Director, 10%+ Owner | Non- Qualified Stock Options (right to buy) | 40K | Jun 30, 2025 | Indirect | ||
| Denali Therapeutics Inc. | Director | Non- Qualified Stock Option (right to buy) | 31.7K | Jun 3, 2025 | Indirect | ||
| Denali Therapeutics Inc. | Director | Non-Qualified Stock Option (right to buy)uy) | 31.7K | Jun 3, 2025 | Indirect | ||
| ACADIA PHARMACEUTICALS INC | Director, 10%+ Owner | Non- Qualified Stock Option (right to buy) | 27.6K | May 29, 2025 | Indirect | ||
| Immunocore Holdings plc | Director | Non-Qualified Share Option (right to buy) | 26.2K | May 15, 2025 | Indirect | ||
| Neoleukin Therapeutics, Inc. | Director, Former 10% Owner | Non-Qualified Stock Option (right to buy) | 25K | Jun 8, 2023 | Indirect | ||
| Talis Biomedical Corp | Director, 10%+ Owner | Non- Qualified Stock Option (right to buy) | 23.7K | Jun 9, 2023 | Indirect | ||
| Prelude Therapeutics Inc | Director, 10%+ Owner | Non- Qualified Stock Option (right to buy) | 23.5K | Jun 14, 2024 | Indirect | ||
| Kymera Therapeutics, Inc. | Director | Non-Qualified Stock Option (right to buy) | 16K | Jun 25, 2025 | Indirect | ||
| Kiniksa Pharmaceuticals, Ltd. | Director | Class A Common Shares | 14.8K | Jun 5, 2024 | Direct | ||
| INCYTE CORP | Director, 10%+ Owner | Non- Qualified Stock Options (right to buy) | 9.22K | Jun 10, 2025 | Indirect | ||
| BICYCLE THERAPEUTICS PLC | Director, 10%+ Owner | Share Option (Right to Buy) | 8.8K | Jan 2, 2025 | Indirect | ||
| vTv Therapeutics Inc. | Director | Non- Qualified Stock Option (right to buy) | 4K | Jun 10, 2025 | Indirect | ||
| MADRIGAL PHARMACEUTICALS, INC. | Director | Non- Qualified Stock Options (right to buy) | 2.58K | Jun 20, 2025 | Indirect | ||
| Immunocore Holdings plc | Director | 2.5% Convertible Senior Notes due 2030 | 0 | Mar 17, 2025 | Indirect | ||
| Seagen Inc. | Director, Former 10% Owner | Common Stock | 0 | $229.00 | Dec 14, 2023 | Direct | |
| Seagen Inc. | Director, Former 10% Owner | Common Stock | 0 | $229.00 | Dec 14, 2023 | Indirect | |
| Seagen Inc. | Director, Former 10% Owner | Stock Options (right to buy) | 0 | Dec 14, 2023 | Indirect |
| Symbol | Company | Period | Transactions | Value $ | Form Type | Date Filed | Role |
|---|---|---|---|---|---|---|---|
| KALA | KALA BIO, Inc. | Sep 30, 2025 | 4 | -$1.06M | 4 | Oct 2, 2025 | Former 10% owner |
| INCY | INCYTE CORP | Sep 30, 2025 | 2 | $0 | 4 | Oct 2, 2025 | Director, 10%+ Owner |
| CELC | Celcuity Inc. | Sep 8, 2025 | 4 | $9.57M | 4 | Sep 10, 2025 | 10%+ Owner |
| VTVT | vTv Therapeutics Inc. | Sep 3, 2025 | 6 | $0 | 4 | Sep 5, 2025 | Director |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Aug 18, 2025 | 26 | $36.9M | 4 | Aug 20, 2025 | Director |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Aug 18, 2025 | 28 | $25M | 4 | Aug 20, 2025 | Director |
| IGMS | IGM Biosciences, Inc. | Aug 14, 2025 | 4 | $0 | 4 | Aug 18, 2025 | Former 10% owner and director |
| CELC | Celcuity Inc. | Aug 1, 2025 | 0 | $0 | 3 | Aug 1, 2025 | 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Jun 30, 2025 | 2 | $0 | 4 | Jul 2, 2025 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Jun 30, 2025 | 2 | $0 | 4 | Jul 2, 2025 | Director, 10%+ Owner |
| TCRX | TScan Therapeutics, Inc. | Jun 30, 2025 | 2 | $0 | 4 | Jul 2, 2025 | Director |
| KOD | Kodiak Sciences Inc. | Jun 30, 2025 | 2 | $0 | 4 | Jul 2, 2025 | Director, 10%+ Owner |
| KYMR | Kymera Therapeutics, Inc. | Jun 30, 2025 | 4 | $57.7M | 4 | Jun 30, 2025 | Director |
| KYMR | Kymera Therapeutics, Inc. | Jun 25, 2025 | 2 | $0 | 4 | Jun 26, 2025 | Director |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Jun 20, 2025 | 4 | $0 | 4 | Jun 24, 2025 | Director |
| PRLD | Prelude Therapeutics Inc | Jun 12, 2025 | 2 | $0 | 4 | Jun 13, 2025 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Jun 10, 2025 | 4 | $0 | 4 | Jun 12, 2025 | Director, 10%+ Owner |
| VTVT | vTv Therapeutics Inc. | Jun 10, 2025 | 2 | $0 | 4 | Jun 12, 2025 | Director |
| KNSA | Kiniksa Pharmaceuticals International, plc | Jun 3, 2025 | 4 | $0 | 4 | Jun 5, 2025 | Director |
| DNLI | Denali Therapeutics Inc. | Jun 3, 2025 | 4 | $0 | 4 | Jun 5, 2025 | Director |
| DNLI | Denali Therapeutics Inc. | Jun 3, 2025 | 0 | $0 | 3 | Jun 5, 2025 | Director |
| ACAD | ACADIA PHARMACEUTICALS INC | May 29, 2025 | 4 | $0 | 4 | Jun 2, 2025 | Director, 10%+ Owner |
| ONC | BeiGene, Ltd. | May 21, 2025 | 4 | $0 | 4 | May 22, 2025 | Director |
| IMCR | Immunocore Holdings plc | May 15, 2025 | 2 | $0 | 4 | May 19, 2025 | Director |
| IGMS | IGM Biosciences, Inc. | Mar 31, 2025 | 2 | $0 | 4 | Apr 2, 2025 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Mar 31, 2025 | 2 | $0 | 4 | Apr 2, 2025 | Director, 10%+ Owner |
| DBVT | DBV Technologies S.A. | Mar 27, 2025 | 4 | $0 | 4 | Mar 31, 2025 | Director, 10%+ Owner |
| IMCR | Immunocore Holdings plc | Mar 17, 2025 | 6 | -$126M | 4 | Mar 19, 2025 | Director |
| REPL | Replimune Group, Inc. | Mar 5, 2025 | 2 | $0 | 4 | Mar 7, 2025 | Director, 10%+ Owner |
| REPL | Replimune Group, Inc. | Mar 5, 2025 | 0 | $0 | 3 | Mar 7, 2025 | Director, 10%+ Owner |
| ONC | BeiGene, Ltd. | Feb 28, 2025 | 2 | -$191M | 4 | Feb 28, 2025 | Director |
| SERA | SERA PROGNOSTICS, INC. | Feb 12, 2025 | 0 | $0 | 3 | Feb 14, 2025 | 10%+ Owner |
| BCYC | BICYCLE THERAPEUTICS PLC | Jan 2, 2025 | 4 | $0 | 4 | Jan 6, 2025 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Dec 31, 2024 | 2 | $0 | 4 | Jan 3, 2025 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Dec 31, 2024 | 2 | $0 | 4 | Jan 3, 2025 | Director, 10%+ Owner |
| KALA | KALA BIO, Inc. | Dec 30, 2024 | 2 | $2M | 4 | Dec 31, 2024 | 10%+ Owner |
| BCYC | BICYCLE THERAPEUTICS PLC | Dec 13, 2024 | 10 | $21.2M | 4 | Dec 17, 2024 | Director, 10%+ Owner |
| BGNE | BeiGene, Ltd. | Dec 9, 2024 | 4 | -$194M | 4 | Dec 10, 2024 | Director |
| KNSA | Kiniksa Pharmaceuticals International, plc | Oct 4, 2024 | 4 | $0 | 4 | Oct 8, 2024 | Director |
| IGMS | IGM Biosciences, Inc. | Sep 30, 2024 | 2 | $0 | 4 | Oct 2, 2024 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Sep 30, 2024 | 2 | $0 | 4 | Oct 2, 2024 | Director, 10%+ Owner |
| KYMR | Kymera Therapeutics, Inc. | Aug 20, 2024 | 3 | $106M | 4 | Aug 22, 2024 | Director |
| IGMS | IGM Biosciences, Inc. | Jun 28, 2024 | 2 | $0 | 4 | Jul 2, 2024 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Jun 28, 2024 | 2 | $0 | 4 | Jul 2, 2024 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Jun 28, 2024 | 2 | $0 | 4 | Jul 2, 2024 | Director, 10%+ Owner |
| KALA | KALA BIO, Inc. | Jun 28, 2024 | 0 | $0 | 3 | Jun 28, 2024 | 10%+ Owner |
| VTVT | vTv Therapeutics Inc. | Jun 25, 2024 | 4 | $0 | 4 | Jun 27, 2024 | Director |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Jun 25, 2024 | 4 | $0 | 4 | Jun 27, 2024 | Director |
| TRDA | Entrada Therapeutics, Inc. | Jun 25, 2024 | 2 | $50M | 4 | Jun 26, 2024 | 10%+ Owner |
| BCYC | BICYCLE THERAPEUTICS PLC | Jun 17, 2024 | 4 | $0 | 4 | Jun 20, 2024 | Director, 10%+ Owner |
| PRLD | Prelude Therapeutics Inc | Jun 14, 2024 | 2 | $0 | 4 | Jun 18, 2024 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Jun 12, 2024 | 6 | -$328M | 4 | Jun 14, 2024 | Director, 10%+ Owner |
| TCRX | TScan Therapeutics, Inc. | Jun 12, 2024 | 2 | $0 | 4 | Jun 14, 2024 | Director |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | Jun 5, 2024 | 4 | $0 | 4 | Jun 7, 2024 | Director |
| BGNE | BeiGene, Ltd. | Jun 5, 2024 | 4 | $0 | 4 | Jun 7, 2024 | Director, 10%+ Owner |
| ACAD | ACADIA PHARMACEUTICALS INC | May 29, 2024 | 4 | $0 | 4 | May 31, 2024 | Director, 10%+ Owner |
| BCYC | BICYCLE THERAPEUTICS plc | May 29, 2024 | 2 | $367M | 4 | May 29, 2024 | Director, 10%+ Owner |
| IMCR | Immunocore Holdings plc | May 28, 2024 | 2 | $0 | 4 | May 29, 2024 | Director |
| IMCR | Immunocore Holdings plc | May 28, 2024 | 0 | $0 | 3 | May 29, 2024 | Director |
| INCY | INCYTE CORP | May 7, 2024 | 4 | $1.47M | 4 | May 9, 2024 | Director, 10%+ Owner |
| TCRX | TScan Therapeutics, Inc. | Apr 19, 2024 | 2 | $69M | 4 | Apr 23, 2024 | Director |
| BCYC | BICYCLE THERAPEUTICS plc | Apr 18, 2024 | 4 | $0 | 4 | Apr 22, 2024 | Director, 10%+ Owner |
| BCYC | BICYCLE THERAPEUTICS plc | Apr 18, 2024 | 0 | $0 | 3 | Apr 18, 2024 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Mar 29, 2024 | 2 | $0 | 4 | Apr 1, 2024 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Mar 28, 2024 | 2 | $0 | 4 | Apr 1, 2024 | Director, 10%+ Owner |
| KYMR | Kymera Therapeutics, Inc. | Mar 28, 2024 | 2 | $0 | 4 | Apr 1, 2024 | Director |
| KYMR | Kymera Therapeutics, Inc. | Mar 28, 2024 | 0 | $0 | 3 | Apr 1, 2024 | Director |
| IGMS | IGM Biosciences, Inc. | Mar 26, 2024 | 8 | $3.43M | 4 | Mar 28, 2024 | Director, 10%+ Owner |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Mar 21, 2024 | 2 | $275M | 4 | Mar 25, 2024 | Director |
| IGMS | IGM Biosciences, Inc. | Mar 12, 2024 | 2 | $0 | 4 | Mar 14, 2024 | Director, 10%+ Owner |
| VTVT | vTv Therapeutics Inc. | Mar 5, 2024 | 4 | $0 | 4 | Mar 7, 2024 | Director |
| VTVT | vTv Therapeutics Inc. | Feb 27, 2024 | 0 | $0 | 3 | Mar 7, 2024 | Director |
| IGMS | IGM Biosciences, Inc. | Dec 29, 2023 | 2 | $0 | 4 | Jan 3, 2024 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Dec 29, 2023 | 2 | $0 | 4 | Jan 3, 2024 | Director, 10%+ Owner |
| NGNE | Neurogene Inc. | Dec 18, 2023 | 8 | $0 | 4 | Dec 20, 2023 | Director, Former 10% Owner |
| SGEN | Seagen Inc. | Dec 14, 2023 | 13 | -$10.2B | 4 | Dec 18, 2023 | Director, Former 10% Owner |
| IGMS | IGM Biosciences, Inc. | Dec 13, 2023 | 12 | $3.43M | 4 | Dec 15, 2023 | Director, 10%+ Owner |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dec 13, 2023 | 24 | $22.5M | 4 | Dec 14, 2023 | Director |
| PRLD | Prelude Therapeutics Inc | Dec 13, 2023 | 2 | $25M | 4 | Dec 13, 2023 | Director, 10%+ Owner |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Dec 12, 2023 | 30 | $7.55M | 4 | Dec 14, 2023 | Director |
| BLCM | BELLICUM PHARMACEUTICALS, INC | Nov 22, 2023 | 4 | $212 | 4 | Nov 24, 2023 | 10%+ Owner |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Nov 21, 2023 | 20 | $12.1M | 4 | Nov 21, 2023 | Director |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Nov 17, 2023 | 30 | $11.9M | 4 | Nov 21, 2023 | Director |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Nov 14, 2023 | 4 | $7.81M | 4 | Nov 15, 2023 | Director |
| BGNE | BeiGene, Ltd. | Nov 14, 2023 | 2 | -$199M | 4 | Nov 14, 2023 | Director, 10%+ Owner |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Nov 13, 2023 | 30 | $15.8M | 4 | Nov 15, 2023 | Director |
| BCEL | Atreca, Inc. | Oct 19, 2023 | 2 | -$111K | 4 | Oct 23, 2023 | Former 10% Owner |
| NLTX | Neoleukin Therapeutics, Inc. | Oct 5, 2023 | 4 | $0 | 4 | Oct 10, 2023 | Director, 10%+ Owner |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Oct 3, 2023 | 2 | $250M | 4 | Oct 5, 2023 | Director |
| IGMS | IGM Biosciences, Inc. | Sep 29, 2023 | 2 | $0 | 4 | Oct 3, 2023 | Director |
| INCY | INCYTE CORP | Sep 29, 2023 | 2 | $0 | 4 | Oct 3, 2023 | Director, 10%+ Owner |
| NLTX | Neoleukin Therapeutics, Inc. | Aug 15, 2023 | 12 | $1.46M | 4 | Aug 17, 2023 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Jun 30, 2023 | 2 | $0 | 4 | Jul 5, 2023 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Jun 30, 2023 | 2 | $0 | 4 | Jul 5, 2023 | Director |
| INCY | INCYTE CORP | Jun 30, 2023 | 2 | $0 | 4 | Jul 5, 2023 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Jun 26, 2023 | 2 | $45M | 4 | Jun 28, 2023 | Director |
| PRLD | Prelude Therapeutics Inc | Jun 16, 2023 | 2 | $0 | 4 | Jun 21, 2023 | Director, 10%+ Owner |
| BGNE | BeiGene, Ltd. | Jun 15, 2023 | 4 | $0 | 4 | Jun 20, 2023 | Director, 10%+ Owner |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Jun 15, 2023 | 2 | $0 | 4 | Jun 20, 2023 | Director |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | Jun 15, 2023 | 0 | $0 | 3 | Jun 20, 2023 | Director |
| INCY | INCYTE CORP | Jun 14, 2023 | 4 | $0 | 4 | Jun 16, 2023 | Director, 10%+ Owner |
| TCRX | TScan Therapeutics, Inc. | Jun 13, 2023 | 2 | $0 | 4 | Jun 15, 2023 | Director |
| TLIS | Talis Biomedical Corp | Jun 9, 2023 | 2 | $0 | 4 | Jun 13, 2023 | Director, 10%+ Owner |
| NLTX | Neoleukin Therapeutics, Inc. | Jun 8, 2023 | 2 | $0 | 4 | Jun 12, 2023 | Director |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | Jun 6, 2023 | 4 | $0 | 4 | Jun 8, 2023 | Director |
| ACAD | ACADIA PHARMACEUTICALS INC | Jun 1, 2023 | 3 | $0 | 4 | Jun 5, 2023 | Director, 10%+ Owner |
| TCRX | TScan Therapeutics, Inc. | Jun 1, 2023 | 2 | $75M | 4 | Jun 2, 2023 | Director |
| SGEN | Seagen Inc. | May 31, 2023 | 2 | $0 | 4 | Jun 2, 2023 | Director, 10%+ Owner |
| ACAD | ACADIA PHARMACEUTICALS INC | May 22, 2023 | 18 | $23.1M | 4 | May 24, 2023 | Director, 10%+ Owner |
| PRLD | Prelude Therapeutics Inc | May 22, 2023 | 4 | $75M | 4 | May 24, 2023 | Director, 10%+ Owner |
| BLCM | BELLICUM PHARMACEUTICALS, INC | May 5, 2023 | 0 | $0 | 3 | May 5, 2023 | 10%+ Owner |
| SGEN | Seagen Inc. | May 1, 2023 | 9 | $642K | 4 | May 3, 2023 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Apr 4, 2023 | 1 | $0 | 4 | Apr 6, 2023 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Mar 31, 2023 | 2 | $0 | 4 | Apr 4, 2023 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Mar 31, 2023 | 2 | $0 | 4 | Apr 4, 2023 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Mar 13, 2023 | 4 | $910K | 4 | Mar 15, 2023 | Director, 10%+ Owner |
| ACAD | ACADIA PHARMACEUTICALS INC | Jan 12, 2023 | 4 | $157K | 4 | Jan 17, 2023 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Dec 30, 2022 | 2 | $0 | 4 | Jan 4, 2023 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Sep 30, 2022 | 2 | $0 | 4 | Oct 4, 2022 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Jun 30, 2022 | 1 | $0 | 4 | Jul 5, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Jun 30, 2022 | 2 | $0 | 4 | Jul 1, 2022 | Director, 10%+ Owner |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | Jun 29, 2022 | 3 | $0 | 4 | Jun 30, 2022 | Director |
| BGNE | BeiGene, Ltd. | Jun 22, 2022 | 3 | $0 | 4 | Jun 24, 2022 | Director, 10%+ Owner |
| PRLD | Prelude Therapeutics Inc | Jun 17, 2022 | 1 | $0 | 4 | Jun 22, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Jun 15, 2022 | 3 | $0 | 4 | Jun 17, 2022 | Director, 10%+ Owner |
| DBVT | DBV Technologies S.A. | Jun 13, 2022 | 4 | $0 | 4 | Jun 13, 2022 | Director, 10%+ Owner |
| TLIS | Talis Biomedical Corp | Jun 10, 2022 | 1 | $0 | 4 | Jun 13, 2022 | Director, 10%+ Owner |
| ACAD | ACADIA PHARMACEUTICALS INC | Jun 7, 2022 | 3 | $0 | 4 | Jun 9, 2022 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Jun 2, 2022 | 12 | $4.45M | 4 | Jun 6, 2022 | Director, 10%+ Owner |
| TRDA | Entrada Therapeutics, Inc. | Jun 2, 2022 | 6 | $261K | 4 | Jun 6, 2022 | 10%+ Owner |
| TCRX | TScan Therapeutics, Inc. | Jun 1, 2022 | 1 | $0 | 4 | Jun 3, 2022 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | May 25, 2022 | 16 | $2.36M | 4 | May 27, 2022 | Director, 10%+ Owner |
| TRDA | Entrada Therapeutics, Inc. | May 20, 2022 | 10 | $282K | 4 | May 24, 2022 | 10%+ Owner |
| TRDA | Entrada Therapeutics, Inc. | May 16, 2022 | 8 | $431K | 4 | May 18, 2022 | 10%+ Owner |
| KOD | Kodiak Sciences Inc. | May 16, 2022 | 14 | $2.7M | 4 | May 18, 2022 | Director, 10%+ Owner |
| SGEN | Seagen Inc. | May 13, 2022 | 3 | $0 | 4 | May 17, 2022 | Director, 10%+ Owner |
| NLTX | Neoleukin Therapeutics, Inc. | May 12, 2022 | 1 | $0 | 4 | May 16, 2022 | Director |
| TCRX | TScan Therapeutics, Inc. | May 10, 2022 | 8 | $2.56M | 4 | May 12, 2022 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Apr 1, 2022 | 2 | $65M | 4 | Apr 5, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Mar 31, 2022 | 2 | $0 | 4 | Apr 4, 2022 | Director, 10%+ Owner |
| IGMS | IGM Biosciences, Inc. | Mar 12, 2022 | 1 | $0 | 4 | Mar 15, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Mar 8, 2022 | 14 | $29M | 4 | Mar 10, 2022 | Director, 10%+ Owner |
| SGEN | Seagen Inc. | Mar 8, 2022 | 4 | $702K | 4 | Mar 10, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Feb 17, 2022 | 8 | $35.7M | 4 | Feb 22, 2022 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Feb 15, 2022 | 10 | $21.8M | 4 | Feb 17, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Feb 10, 2022 | 7 | $107M | 4 | Feb 14, 2022 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Jan 27, 2022 | 12 | $18.1M | 4 | Jan 31, 2022 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Jan 21, 2022 | 10 | $28.8M | 4 | Jan 25, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Dec 31, 2021 | 2 | $0 | 4 | Jan 4, 2022 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Dec 15, 2021 | 10 | $116M | 4 | Dec 17, 2021 | Director, 10%+ Owner |
| TRDA | Entrada Therapeutics, Inc. | Dec 14, 2021 | 0 | $0 | 3 | Dec 16, 2021 | 10%+ Owner |
| SGEN | Seagen Inc. | Nov 30, 2021 | 20 | -$63.4M | 4 | Dec 2, 2021 | Director, 10%+ Owner |
| TLIS | Talis Biomedical Corp | Nov 18, 2021 | 1 | $218K | 4 | Nov 19, 2021 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Sep 30, 2021 | 2 | $0 | 4 | Oct 4, 2021 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Sep 29, 2021 | 7 | $8.33M | 4 | Oct 1, 2021 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Sep 15, 2021 | 3 | $3.01M | 4 | Sep 17, 2021 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Sep 7, 2021 | 2 | $5.37M | 4 | Sep 9, 2021 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Aug 17, 2021 | 10 | $10M | 4 | Aug 19, 2021 | Director, 10%+ Owner |
| KOD | Kodiak Sciences Inc. | Aug 11, 2021 | 10 | $8.96M | 4 | Aug 13, 2021 | Director, 10%+ Owner |
| TCRX | TScan Therapeutics, Inc. | Jul 20, 2021 | 6 | $21.4M | 4 | Jul 22, 2021 | Director |
| TCRX | TScan Therapeutics, Inc. | Jul 15, 2021 | 0 | $0 | 3 | Jul 15, 2021 | Director, 10%+ Owner |
| INCY | INCYTE CORP | Jun 30, 2021 | 2 | $0 | 4 | Jul 2, 2021 | Director, 10%+ Owner |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | Jun 29, 2021 | 1 | $0 | 4 | Jul 1, 2021 | Director |
| KOD | Kodiak Sciences Inc. | Jun 28, 2021 | 14 | $23.7M | 4 | Jun 30, 2021 | Director, 10%+ Owner |
| ACAD | ACADIA PHARMACEUTICALS INC | Jun 22, 2021 | 3 | $0 | 4 | Jun 24, 2021 | Director, 10%+ Owner |
| PRLD | Prelude Therapeutics Inc | Jun 18, 2021 | 1 | $0 | 4 | Jun 22, 2021 | Director, 10%+ Owner |
| BGNE | BeiGene, Ltd. | Jun 16, 2021 | 3 | $0 | 4 | Jun 21, 2021 | Director, 10%+ Owner |
| AGLE | Aeglea BioTherapeutics, Inc. | Jun 8, 2021 | 1 | $0 | 4 | Jun 10, 2021 | Director |
| INCY | INCYTE CORP | May 26, 2021 | 3 | $0 | 4 | May 28, 2021 | Director, 10%+ Owner |
| INCY | INCYTE CORP | May 14, 2021 | 4 | $759K | 4 | May 18, 2021 | Director, 10%+ Owner |
| SGEN | Seagen Inc. | May 14, 2021 | 7 | $666K | 4 | May 18, 2021 | Director, 10%+ Owner |
| NLTX | Neoleukin Therapeutics, Inc. | May 11, 2021 | 1 | $0 | 4 | May 13, 2021 | Director |